galunisertib + durvalumab

**Galunisertib + durvalumab** is a combination investigational regimen comprised of **galunisertib**, an oral small-molecule inhibitor of transforming growth factor beta receptor I (TGFβ-RI/ALK5), and **durvalumab**, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Galunisertib acts as a selective inhibitor of TGFβ signaling, which is implicated in tumor microenvironment modulation and immune evasion. Durvalumab blocks the PD-1/PD-L1 immune checkpoint pathway, enhancing T-cell-mediated antitumor immune responses. This combination has been studied primarily in metastatic pancreatic cancer to evaluate the safety and preliminary efficacy of targeting both immune evasion (via checkpoint inhibition) and the immunosuppressive tumor microenvironment (via TGFβ inhibition)[1][2][3].